{
    "id": 3507,
    "name": "dermatofibrosarcoma protuberans",
    "source": "DOID",
    "definition": "A fibrosarcoma that is located_in the dermis laryer of the skin and that begins as a hard nodule and grows slowly. [url:http\\://en.wikipedia.org/wiki/Dermatofibrosarcoma_protuberans, url:http\\://www.cancer.gov/dictionary?CdrID=44276]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:3507",
    "evidence": [
        {
            "id": 1977,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial that supported FDA approval, treatment with Gleevec (imatinib) resulted in a median time-to-progression of 23.9 months, and complete response in 33% (4/12) and partial response in 50% (6/12) of patients with dermatofibrosarcoma protuberans (PMID: 18451237).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3507,
                "name": "dermatofibrosarcoma protuberans",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6183,
                    "pubMedId": 18451237,
                    "title": "Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18451237"
                },
                {
                    "id": 15459,
                    "pubMedId": null,
                    "title": "Gleevec (imatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021588"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2930,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, Kisqali (ribociclib) inhibited proliferation of a Gleevec (imatinib)-resistant dermatofibroscarcoma cell line harboring deletion of both CDKN2A and CDKN2B and a PDGFB rearrangement (PMID: 25852058).",
            "molecularProfile": {
                "id": 10737,
                "profileName": "PDGFB fusion CDKN2A del CDKN2B del"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3507,
                "name": "dermatofibrosarcoma protuberans",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3535,
                    "pubMedId": 25852058,
                    "title": "CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25852058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4622,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Gleevec (imatinib) treatment in patients with fibrosarcomatous-dermatofibrosarcoma protuberans harboring COL1A1-PDGFB resulted in a progression free survival of 11 months, a partial response of 80% (8/10), one patient (1/10) with stable disease, and one patient (1/10) with progressive disease (PMID: 26261104).",
            "molecularProfile": {
                "id": 18613,
                "profileName": "COL1A1 - PDGFB"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3507,
                "name": "dermatofibrosarcoma protuberans",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4635,
                    "pubMedId": 26261104,
                    "title": "Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26261104"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12923,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "COL1A1-PDGFRB fusions aid the diagnosis of dermatofibrosarcoma protuberans (NCCN.org).",
            "molecularProfile": {
                "id": 18613,
                "profileName": "COL1A1 - PDGFB"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3507,
                "name": "dermatofibrosarcoma protuberans",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01446809",
            "title": "Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1472,
                    "therapyName": "Doxorubicin + Ifosfamide",
                    "synonyms": null
                },
                {
                    "id": 1471,
                    "therapyName": "Doxorubicin + Ifosfamide + Pazopanib",
                    "synonyms": null
                }
            ]
        }
    ]
}